Literature DB >> 27819528

Interferon-gamma (IFN-γ) is Elevated in Wound Exudate from Hidradenitis Suppurativa.

Anirban Banerjee1, Sean McNish1, Victoria K Shanmugam1.   

Abstract

Hidradenitis suppurativa (HS) is a chronic recurrent inflammatory disease of apocrine glands which affects 1-4% of young adults. The purpose of this study was to investigate inflammatory cytokines in effluent from HS lesions and to identify potential local drivers of inflammation in HS. Wound fluid specimens from HS patients (n = 8) and age-matched chronic wound patients (n = 8) were selected for analysis. The hidradenitis suppurativa score (HSS) was used to determine the extent of HS activity. Cytokine analysis was conducted using Meso Scale Discovery cytokine and proinflammatory panels. Interferon-gamma (IFN-γ) was significantly elevated in the HS effluent compared to chronic wounds (1418 ± 1501 pg/ml compared to 102.5 ± 138 pg/ml, p = 0.027). HS effluent also had significantly higher levels of tumor necrosis factor-β (TNF-β) (9.24 ± 7.22 pg/ml compared to 1.65 ± 2.14 pg/ml, p = 0.03). There was no significant difference in any other cytokines. There was no significant difference in demographics in the HS compared to chronic wound cohorts. Mean HSS in the HS cohort was 68.88 (SD ± 41.45). In this proof-of-concept pilot study, IFN-γ was significantly elevated in HS effluent. TNF-β/LT-α levels were also elevated in HS, although the levels were more modest. Further studies should focus on molecular drivers of tissue injury in HS and the relationship between HS effluent cytokine profile and disease activity.

Entities:  

Keywords:  Cytokine; IFN-γ; hidradenitis suppurativa; ulcer; wound; wound effluent; wound fluid

Mesh:

Substances:

Year:  2016        PMID: 27819528      PMCID: PMC5767159          DOI: 10.1080/08820139.2016.1230867

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  54 in total

1.  Questionnaire-based diagnosis of hidradenitis suppurativa: specificity, sensitivity and positive predictive value of specific diagnostic questions.

Authors:  S Esmann; D N Dufour; G B E Jemec
Journal:  Br J Dermatol       Date:  2010-01-17       Impact factor: 9.302

2.  Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling.

Authors:  Ferdousi Chowdhury; Anthony Williams; Peter Johnson
Journal:  J Immunol Methods       Date:  2008-11-05       Impact factor: 2.303

Review 3.  The clinical efficacy of two semi-quantitative wound-swabbing techniques in identifying the causative organism(s) in infected cutaneous wounds.

Authors:  Donna E Angel; Peter Lloyd; Keryln Carville; Nick Santamaria
Journal:  Int Wound J       Date:  2011-02-09       Impact factor: 3.315

Review 4.  Hidradenitis suppurativa: the role of immune dysregulation.

Authors:  Genevieve Kelly; Cheryl M Sweeney; Anne-Marie Tobin; Brian Kirby
Journal:  Int J Dermatol       Date:  2014-06-25       Impact factor: 2.736

5.  A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.

Authors:  Masahiro Amano; Annika Grant; Francisco A Kerdel
Journal:  Int J Dermatol       Date:  2010-08       Impact factor: 2.736

Review 6.  Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors.

Authors:  Pia Haslund; Robert A Lee; Gregor B E Jemec
Journal:  Acta Derm Venereol       Date:  2009-11       Impact factor: 4.437

7.  Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa.

Authors:  V U Emelianov; F G Bechara; R Gläser; E A Langan; W M Taungjaruwinai; J M Schröder; K C Meyer; R Paus
Journal:  Br J Dermatol       Date:  2012-04-04       Impact factor: 9.302

8.  Interobserver variability of clinical scores in hidradenitis suppurativa is low.

Authors:  K Sartorius; H Killasli; J Heilborn; G B E Jemec; J Lapins; L Emtestam
Journal:  Br J Dermatol       Date:  2010-02-22       Impact factor: 9.302

9.  A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.

Authors:  I Miller; C D Lynggaard; S Lophaven; C Zachariae; D N Dufour; G B E Jemec
Journal:  Br J Dermatol       Date:  2011-06-30       Impact factor: 9.302

10.  Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.

Authors:  Alexa B Kimball; Francisco Kerdel; David Adams; Ulrich Mrowietz; Joel M Gelfand; Robert Gniadecki; Errol P Prens; Joel Schlessinger; Christos C Zouboulis; Hessel H van der Zee; Marie Rosenfeld; Parvez Mulani; Yihua Gu; Susan Paulson; Martin Okun; Gregor B E Jemec
Journal:  Ann Intern Med       Date:  2012-12-18       Impact factor: 25.391

View more
  13 in total

1.  Prevalence of positive QuantiFERON gold in-tube testing in hidradenitis suppurativa.

Authors:  Tina Boortalary; Kanchan Misra; Sean McNish; Derek Jones; Victoria K Shanmugam
Journal:  J Dermatolog Treat       Date:  2018-01-22       Impact factor: 3.359

Review 2.  The critical role of macrophages in the pathogenesis of hidradenitis suppurativa.

Authors:  Ahmed Shah; Raed Alhusayen; Saeid Amini-Nik
Journal:  Inflamm Res       Date:  2017-06-27       Impact factor: 4.575

3.  Inherent differences in keratinocyte function in hidradenitis suppurativa: Evidence for the role of IL-22 in disease pathogenesis.

Authors:  Derek Jones; Anirban Banerjee; Peter Z Berger; Alexandra Gross; Sean McNish; Richard Amdur; Victoria K Shanmugam
Journal:  Immunol Invest       Date:  2017-10-03       Impact factor: 3.657

Review 4.  Review of Current Immunologic Therapies for Hidradenitis Suppurativa.

Authors:  Victoria K Shanmugam; Nadia Meher Zaman; Sean McNish; Faye N Hant
Journal:  Int J Rheumatol       Date:  2017-08-20

5.  Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model.

Authors:  Allard R J V Vossen; Hessel H van der Zee; Errol P Prens
Journal:  Front Immunol       Date:  2018-12-14       Impact factor: 7.561

6.  A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa.

Authors:  John W Frew; Jason E Hawkes; James G Krueger
Journal:  F1000Res       Date:  2018-12-13

7.  Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa.

Authors:  Ester Del Duca; Paola Morelli; Luigi Bennardo; Cosimo Di Raimondo; Steven Paul Nisticò
Journal:  Int J Mol Sci       Date:  2020-11-10       Impact factor: 5.923

Review 8.  Hidradenitis Suppurativa: Host-Microbe and Immune Pathogenesis Underlie Important Future Directions.

Authors:  Simon W Jiang; Melodi Javid Whitley; Paula Mariottoni; Tarannum Jaleel; Amanda S MacLeod
Journal:  JID Innov       Date:  2021-01-12

9.  The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris.

Authors:  Kristina Navrazhina; Sandra Garcet; John W Frew; Xiuzhong Zheng; Israel Coats; Emma Guttman-Yassky; James G Krueger
Journal:  J Am Acad Dermatol       Date:  2021-07-30       Impact factor: 11.527

10.  Single-Cell RNA Sequencing Reveals Cellular and Transcriptional Changes Associated With M1 Macrophage Polarization in Hidradenitis Suppurativa.

Authors:  Paula Mariottoni; Simon W Jiang; Courtney A Prestwood; Vaibhav Jain; Jutamas Suwanpradid; Melodi Javid Whitley; Margaret Coates; David A Brown; Detlev Erdmann; David L Corcoran; Simon G Gregory; Tarannum Jaleel; Jennifer Y Zhang; Tamia A Harris-Tryon; Amanda S MacLeod
Journal:  Front Med (Lausanne)       Date:  2021-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.